BackBioSyent Overview

BioSyent Profit Margin

Latest profit margin for BioSyent: 15.81% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

14.24%
↓ 35.11% YoY

As of Sep 2026

Annual Profit Margin (TTM)

15.81%
↓ 22.76% YoY

Trailing 12 months ending Sep 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

BioSyent (RX.V) FAQ

The latest profit margin for RX.V is 15.81% as of September 2026. That compares with 20.47% in the prior-year period — down 22.8% year over year. That is above the sector sector average of 13.4%. Investors often review this figure alongside BioSyent's historical trend and sector peers before judging valuation or financial health.

Over the past year, RX.V's profit margin moved from 20.47% to 15.81% — a 22.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BioSyent's valuation or profitability profile.

Against its sector companies, RX.V currently prints 15.81% for profit margin, while the sector average sits near 13.4%. That is roughly 18.0% above the sector mean. Large gaps often invite a closer look at BioSyent's growth, margins, and balance sheet.

Profit Margin shows how effectively BioSyent converts resources into returns. At 15.81%, RX.V may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 20.47% in the prior-year period — down 22.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RX.V's profit margin (15.81%), review year-over-year change from 20.47%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers